

Figure S1. *Ex vivo* VOR failed to induce a statistically significant increase in rca-HIV RNA in resting CD4+ T cells isolated from aviremic participants V-13, V-14, V-15 and V-16. Pools of 24 million resting CD4+ T cells isolated from aviremic donors were exposed to VOR or mitogen (PHA and 60 U/ml IL-2) for 6hrs and rca-HIV RNA measured as described. LOQ: limit of quantitation.



Figure S2. A single 400 mg dose of VOR failed to significantly increase HIV *gag* RNA in the resting CD4+ T cells of aviremic participants V-6, V-7, V-8, V-9 and V-12. rca-HIV RNA was measured from pools of 36 million resting CD4+ T cells as described.



Figure S3. Minimal variation of baseline rca-RNA over time from the cells of participants that were analyzed at different times demonstrate that the increase in rcaRNA observed after VOR dosing is not due to changes in baseline rcaRNA. Baseline1: at single Dose measurement; Baseline 2: at paired dose measurement; Baseline 3: at the 10 doses measurement.

Table S1. Quantitative virus outgrowth (QVOA)

Participant ID	Resting CD4+ T cell Infection (infected cells per million resting CD4+ T cells)			
	Baseline	**Single Dose**	**Paired Doses**	**Multiple Doses**
V-1	0.526	n.d.	0.323	n.d.
V-2	0.953	n.d.	0.854	n.d.
V-3	1.662	8.394	0.528	0.351
V-4	0.439	0.489	0.323	0.890
V-5	0.278	0.101	0.043	0.084
V-10	1.646	0.779	0.859	n.d.
V-11	0.342	0.406	0.485 (48hr) 0.164 (72hr)	n.d.

Table S2. Change in absolute CD4/CD8 count overtime during VOR study

PID	Treatment	CD4 count (%)	CD8 count (%)
V-3	Baseline	1045 (41.8)	925 (37)
	Single Dose	832 (37.8)*	871 (39.6)*
	Paired Dose	874 (38)*	902 (39.2)*
	10 doses	972 (34.7)	1156 (41.3)
V-4	Baseline	474 (31.6)	551 (36.7)
	Single Dose	446(34.3)	482 (37.1)
	Paired Dose	329 (29.9)	400 (36.4)
	10 doses	385 (27.5)	549 (39.2)
V-5	Baseline	610 (38.1)	450 (28.1)
	Single Dose	394 (35.8)*	270 (24.5)*
	Paired Dose	n/d	n/d
	10 doses	600 (35.3)	500 (29.4)

*Measurements taken within 2 months of dose
n/d: not done